Trial Profile
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs LY 3200882 (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Glioma; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly and Company
- 20 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 19 Sep 2022 Planned End Date changed from 30 Dec 2022 to 1 Aug 2023.
- 12 Sep 2021 Results published in the Clinical Cancer Research